Investigators have completed the algorithm development and clinical validation studies of objective, electroencephalogram-based technology in adolescent and young adult populations, the company says. The studies were funded by a $9.9m research contract from the US Department of Defense, award funding from the National Football League-GE Head Health Challenge, and BrainScope.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injury. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.

BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injuries. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.